Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis
Allison A. Throm, … , Lauren M. Pachman, Anthony R. French
Allison A. Throm, … , Lauren M. Pachman, Anthony R. French
Published November 15, 2018
Citation Information: JCI Insight. 2018;3(22):e123236. https://doi.org/10.1172/jci.insight.123236.
View: Text | PDF
Research Article Immunology

Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis

  • Text
  • PDF
Abstract

Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting with characteristic rash and muscle weakness. To delineate signaling abnormalities in JDM, mass cytometry was performed with PBMCs from treatment-naive JDM patients and controls. NK cell percentages were lower while frequencies of naive B cells and naive CD4+ T cells were higher in JDM patients than in controls. These cell frequency differences were attenuated with cessation of active disease. A large number of signaling differences were identified in treatment-naive JDM patients compared with controls. Classification models incorporating feature selection demonstrated that differences in phospholipase Cγ2 (PLCγ2) phosphorylation comprised 10 of 12 features (i.e., phosphoprotein in a specific immune cell subset) distinguishing the 2 groups. Because NK cells represented 5 of these 12 features, further studies focused on the PLCγ2 pathway in NK cells, which is responsible for stimulating calcium flux and cytotoxic granule movement. No differences were detected in upstream signaling or total PLCγ2 protein levels. Hypophosphorylation of PLCγ2 and downstream mitogen-activated protein kinase-activated protein kinase 2 were partially attenuated with cessation of active disease. PLCγ2 hypophosphorylation in treatment-naive JDM patients resulted in decreased calcium flux. The identification of dysregulation of PLCγ2 phosphorylation and decreased calcium flux in NK cells provides potential mechanistic insight into JDM pathogenesis.

Authors

Allison A. Throm, Joshua B. Alinger, Jeanette T. Pingel, Allyssa L. Daugherty, Lauren M. Pachman, Anthony R. French

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 Total
Citations: 2 4 1 2 5 1 2 17
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (17)

Title and authors Publication Year
Mass cytometry: exploring the immune landscape of systemic autoimmune and inflammatory diseases in the past fourteen years
Kante A, Chevalier MF, Sène D, Chauffier J, Mouly S, Chousterman BG, Azibani F, Terrier B, Pezel T, Comarmond C
Frontiers in Immunology 2025
Psychometric Properties of Patient-Reported Outcomes Measurement Information System (PROMIS) Fixed Short Forms in Juvenile Myositis
Ardalan K, Marques MC, Cella D, Curran ML, Gray EL, Lee J, Fahey KJ, Wolfe ML, Pachman LM, Chang RW
Seminars in arthritis and rheumatism 2025
Coordinated immune dysregulation in Juvenile Dermatomyositis revealed by single-cell genomics
Gabrielle Rabadam, Camilla Wibrand, Emily Flynn, George Hartoularos, Yang Sun, Jimmie Ye, Susan Kim, Zev Gartner, Marina Sirota, Jessica Neely
JCI Insight 2024
Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness
Khojah A, Pachman LM, Bukhari A, Trinh C, Morgan G, Pandey S, Le Poole IC, Klein-Gitelman MS
International journal of molecular sciences 2024
Single-cell mass cytometry in immunological skin diseases
Zhao M, Cheng Y, Gao J, Zhou F
Frontiers in immunology 2024
Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies.
Kim H
Paediatric drugs 2024
Coordinated immune dysregulation in Juvenile Dermatomyositis revealed by single-cell genomics
Rabadam G, Wibrand C, Flynn E, Hartoularos GC, Sun Y, Ye CJ, Kim S, Gartner Z, Sirota M, Neely J
2023
Multi-modal single-cell sequencing identifies cellular immunophenotypes associated with juvenile dermatomyositis disease activity
Jessica Neely, George Hartoularos, Daniel Bunis, Yang Sun, David Lee, Susan Kim, Jimmie Ye, Marina Sirota
Frontiers in immunology 2022
Expansion of a novel population of NK cells with low ribosome expression in juvenile dermatomyositis
Hilliard KA, Throm AA, Pingel JT, Saucier N, Zaher HS, French AR
Frontiers in immunology 2022
Natural killer cells in inflammatory autoimmune diseases
Y Yang, J Day, FS Guimaraes, IP Wicks, C Louis
IBMS BoneKEy 2021
CD4+ T cells from children with active juvenile idiopathic arthritis show altered chromatin features associated with transcriptional abnormalities
E Tarbell, K Jiang, TR Hennon, L Holmes, S Williams, Y Fu, PM Gaffney, T Liu, JN Jarvis
Scientific Reports 2021
Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy
LM Pachman, BE Nolan, D DeRanieri, AM Khojah
Current Treatment Options in Rheumatology 2021
The Role of Immune Cells in the Pathogenesis of Idiopathic Inflammatory Myopathies
L Zhao, Q Wang, B Zhou, L Zhang, H Zhu
Aging and disease 2021
MECHANISTIC AND DATA-DRIVEN MODELS OF CELL SIGNALING: TOOLS FOR FUNDAMENTAL DISCOVERY AND RATIONAL DESIGN OF THERAPY.
Myers PJ, Lee SH, Lazzara MJ
Current Opinion in Systems Biology 2021
Serum protein biomarkers for juvenile dermatomyositis: a pilot study
SM Tawalbeh, W Marin, GA Morgan, UJ Dang, Y Hathout, LM Pachman
BMC Rheumatology 2020
Immunomics in Pediatric Rheumatic Diseases
SH Tay, KN Yaung, JY Leong, JG Yeo, T Arkachaisri, S Albani
Frontiers in Medicine 2019
Advances Toward Precision Medicine in Juvenile Dermatomyositis
J Neely, S Kim
Current Rheumatology Reports 2019

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts